A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863

Annals of Oncology

Volumn 14, Issue 12, 2003, Pages 1783-1790

  Venook, A P ^a,k   Klein, C Enders ^b   Fleming, G ^j   Hollis, D ^c   Leichman, C G ^d   Hohl, R ^e   Byrd, J ^f   Budman, D ^g   Villalona, M ^h   Marshall, J ⁱ   Rosner, G L ^c   Ramirez, J ^j   Kastrissios, H ^b   Ratain, M J ^j  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c CALGB Statistical Center   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^f WALTER REED ARMY MEDICAL CENTER   (United States)

^g NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ GEORGETOWN UNIVERSITY   (United States)

^j UNIVERSITY OF CHICAGO   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Hepatic dysfunction; Irinotecan; Pharmacokinetics

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; ASPARTATE AMINOTRANSFERASE; ATROPINE; BILIRUBIN GLUCURONIDE; CAMPTOTHECIN DERIVATIVE; CREATININE; DRUG METABOLITE; IRINOTECAN; MELPHALAN; MITOMYCIN C; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID;

ADULT; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLEEDING DISORDER; BLOOD TOXICITY; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG METABOLISM; DRUG SENSITIVITY; DYSPHAGIA; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HYPERBILIRUBINEMIA; INFECTION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER TOXICITY; LYMPHOMA; MALE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PELVIS RADIOGRAPHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RISK ASSESSMENT; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 9144256327     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg493     Document Type: Article

References (20)

1. Cunningham D, Pyrhonen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418.
2. Rougier P, Cutsem EV, Bajetta E et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorourcail in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412.
3. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
4. Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000; 343: 905-914.
5. Kehrer DFS, Sparreboom A, Verweij J et al. Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. Clin Cancer Res 2001; 7: 1136-1141.
6. Abigerges D, Armand JP, Chabot GC et al. High dose intensity of CPT-11 administered as single dose every three weeks: the Institut Gustave Roussy experience. Proc Am Soc Clin Oncol 1993; 12: 133(Abstr 332).
7. Rothenberg ML, Meropol NJ, Poplin EA et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19: 3801-3807.
8. Wasserman E, Myara A, Lokiec F et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 1997; 8: 1049-1051.
9. Gupta E, Lestingi RM, Mick R et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994; 54: 3723-3725.
10. Mick R, Gupta E, Vokes EE et al. Limited-sampling models for Irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. J Clin Oncol 1996; 14: 2012-2019.
11. Venook AP, Egorin MJ, Rosner GL et al. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol 1998; 16: 1811-1819.
12. Venook AP, Egorin MJ, Rosner GL et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 2000; 18: 2780-2787.
13. Klein C, Gupta E, Reid JM et al. A pharmacokinetic model for irinotecan and its metabolites, SN38 and SN38 glucuronide. Clin Pharmacol Ther 2002; 72: 638-647.
14. Pitot HC, Goldberg RM, Reid JM et al. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy. Clin Cancer Res 2000; 6: 2236-2244.
15. Iyer L, Das S, Janisch Let al. UGT1A1 *28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2: 43-47.
16. Beal SL, Sheiner LB. NONMEM Users guide - Part I Users Basic Guide. NONMEM Project Group, 1992.
17. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989; 7: 1748-1756.
18. Stewart CF, Arbuck SG, Fleming RA et al. Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. J Clin Oncol 1990; 8: 1874-1879.
19. Raymond E, Boige V, Faivre S et al. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J Clin Oncol 2002; 20: 4303-4312.
20. Mathijssen RHJ, Verweij J, de Jonge MJA et al. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol 2002; 20: 81-87.